幽门螺杆菌感染激活NF-κB信号通路促进胃癌SGC-7901细胞炎症因子释放

为了探讨幽门螺杆菌对胃癌SGC-7901细胞炎症因子释放的影响,本研究将幽门螺杆菌感染SGC-7901细胞后,采用细胞计数盒(CCK-8)检测SGC-7901细胞活力,酶联免疫吸附实验(ELISA)检测炎症因子TNF-α、IL-1β以及IL-8的水平,Real-time PCR检测细胞TNF-α、IL-1β以及IL-8 m RNA的表达,蛋白免疫印迹法(Western blotting)检测NF-κB信号通路相关蛋白NF-κB p65蛋白表达以及IκBα磷酸化水平。研究结果表明,幽门螺杆菌感染后,SGC-7901细胞活力显著增加;幽门螺杆菌感染明显上调SGC-7901细胞TNF-α、IL-1β以及IL-8 mRNA的表达;本研究还进一步发现幽门螺杆菌感染显著增加SGC-7901细胞TNF-α、IL-1β以及IL-8的水平;此外,幽门螺杆菌处理的SGC-7901细胞,其NF-κB p65的蛋白表达以及IκBα磷酸化水平均显著上调。本研究的结论初步表明,幽门螺杆菌感染促进胃癌SGC-7901细胞炎症因子的释放,其机制可能涉及激活NF-κB信号通路。     

乳酸调控大鼠肠黏膜微血管内皮细胞的NF-κB信号通路

目的探讨内毒素（LPS）刺激大鼠肠黏膜微血管内皮细胞（RIMMVECs）后,乳酸（LA）调控NF-κB信号通路中磷酸化IκBα和NF-κB p65蛋白表达情况,肿瘤坏死因子α（TNF-α）和白细胞介素6（IL-6）mRNA表达情况,阐明乳酸发挥作用的最佳时间及其调控NF-κB信号通路的部位。方法提取RIMMVECs总蛋白和总RNA,用Western blotting检测NF-κB p65、IκBα及p-IκBα蛋白表达水平,用real-time PCR对TNF-α和IL-6 mRNA进行定量检测。结果乳酸能降低LPS诱导RIMMVECs分泌的TNF-α和IL-6 mRNA表达水平,并分别于24 h和3 h下调效果最明显;乳酸能抑制IκBα磷酸化及NF-κB转录活性,并于4～8 h达到最佳效果;乳酸发挥作用部位是抑制信号通路中IκBα磷酸化。结论乳酸通过抑制IκBα磷酸化而阻断NF-κB的激活,抑制下游炎性因子表达,进而发挥出很好的预防炎症效果。     

rVvhA作用于THP-1细胞NF-κB信号通路的研究

研究重组创伤弧菌溶细胞素（rVvhA）对人单核细胞系（THP-1）NF-κB信号通路的影响。应用CCK-8法检测rVvhA对THP-1细胞增殖的抑制作用;倒置显微镜和激光共聚焦显微镜观察rVvhA作用后细胞的形态学变化和细胞内NF-κB p65的核转移情况;应用流式细胞仪和Westernblot检测rVvhA作用后细胞浆内和细胞核内NF-κB p65的表达情况;ELISA检测rVvhA作用于细胞后TNF-α、IL-6表达含量的变化。试验结果显示：rVvhA能够呈时间–剂量依赖性地抑制THP-1细胞的生长,且镜下可见明显的细胞形态学变化。激光共聚焦显示0.4 HU/mL rVvhA作用6 h后,THP-1细胞内NF-κB p65的核转移现象最明显;流式细胞仪结果显示0.6 HU/mL rVvhA作用2 h后,细胞内总的NF-κB p65表达量达到高峰;Western blot检测显示0.6 HU/mL rVvhA作用4 h时细胞核内NF-κBp65蛋白含量最高;ELISA显示TNF-α的表达在rVvhA作用的适当范围内呈时间–剂量依赖性变化;IL-6在0.6 HU/mL rVvhA作用时表达量最高,随后随着浓度的增加反而下降;NF-κB抑制剂能使IL-6表达量下调。实验证明rVvhA作用于THP-1细胞后能激活NF-κB信号通路,上调TNF-α、IL-6的表达,而NF-κB抑制剂能够下调IL-6的表达。     

PRMT6过表达在NF-κB/p65介导小鼠肺气肿炎症反应中的作用

[目的]观察蛋白精氨酸甲基转移酶6(PRMT6)过表达在NF-κB/p65介导小鼠肺气肿模型炎症反应中的作用及机制。[方法]80只Balb/c小鼠暴露于香烟烟雾建立肺气肿模型,随机分为阴性对照组、模型组、阳性对照组(空白慢病毒载体气管内滴注)和PRMT6过表达组(PRMT6慢病毒载体气管内滴注)各20只。HE法观察肺组织形态学,Western Blot测定肺组织PRMT6表达。ELISA测定肺泡灌洗液(BALF)和肺组织匀浆中肿瘤坏死因子-α(TNF-α)和白细胞介素-8(IL-8)水平。[结果]与阴性对照组比较,模型组和阳性对照组小鼠气道阻力、BALF和肺组织匀浆TNF-α及IL-8水平、肺组织NF-κB/p65表达均升高,动态肺顺应性、肺组织PRMT6相对表达量降低(P<0.05);与模型组和阳性对照组比较,PRMT6过表达组小鼠气道阻力、BALF和肺组织匀浆TNF-α及IL-8水平、肺组织NF-κB/p65表达降低,动态肺顺应性、肺组织PRMT6相对表达水平升高(P<0.05)。[结论]PRMT6过表达可能通过抑制肺气肿小鼠肺组织NF-κB/p65核转位,发挥抗炎作用,改善肺功能。     

五灵胶囊对LPS诱导鼠枯否细胞p38MAPK信号转导通路的影响

目的:探讨五灵胶囊对脂多糖(LPS)诱导的大鼠枯否细胞(Kupffer cells,KC)p38MAPK信号转导通路的影响。方法:分离纯化KCs,60ng/ml LPS刺激建立LPS的肝细胞损伤模型;40只SD大鼠药物处理后,分离制备含药血清。实验分为四组:空白血清组、LPS+空白血清组、含药血清Ⅰ组(10.0g/kg)+LPS、含药血清Ⅱ组(6.25g/kg)+LPS。KCs产生促炎因子(I125放免法测定TNF-α、IL-6、IL-8,比色法测定NO生成量),采用Western blot法检测ERK、p-ERK、p38、p-p38、TNF-α和STAT3的蛋白水平。结果:1、空白血清+LPS组,TNF-α、IL-6、IL-8和NO浓度明显高于空白血清组;2、同空白血清+LPS组比较,含药血清Ⅰ、Ⅱ组TNF-α、IL-6、IL-8和NO水平明显降低;3、与空白血清组比较,空白血清+LPS组能上调KCs对p-ERK、P38、p-P38、STAT3和TNF-α表达(p<0.01,p<0.05),对ERK表达无影响(p>0.05)4、同空白血清+LPS组比较,含药血清Ⅰ+LPS、含药血清Ⅱ+LPS组p-p38、S...     

IL-6/STAT3信号途径介导肉芽肿性乳腺炎的作用研究

目的:探讨IL-6/STAT3信号途径介导肉芽肿性乳腺炎的机制研究及临床意义。方法:收集我院2017年1月至2017年6月收治入住的30例肉芽肿性乳腺炎患者及30例普通患者的血清样本,对肉芽肿性乳腺炎患者同时采集炎性肿块组织样本及距离炎性肿块边缘大于等于3 cm且镜检为正常乳腺组织的样本。采用ELISA法检测血清样本中的IL-6的表达水平,同时采用Western blot检测组织样本中IL-6和pSTAT3蛋白的表达水平并分析二者的相关性。结果:与普通患者血清样本相比,肉芽肿性乳腺炎患者血清中IL-6的表达水平明显增高(P0.05),肉芽肿性乳腺炎组织样本中IL-6和pSTAT3蛋白的表达水平明显高于毗邻的正常乳腺组织(P0.01),IL-6表达与组织STAT3磷酸化水平具有明显的正相关性(r=0.353,P0.05)。结论:IL-6/STAT3信号途径可能介导肉芽肿性乳腺炎的发生发展。     

miR-124-3p靶向TLR4抑制流感病毒性肺炎小鼠的炎症反应

目的:探讨miR-124-3p靶向Toll样受体4(TLR4)对流感病毒性肺炎小鼠炎症反应的影响。方法:建立流感病毒亚洲甲型鼠肺适应株(FM1)感染所致病毒性肺炎小鼠模型,采用RT-qPCR测定肺组织miRNA-124-3p表达水平。病毒性肺炎小鼠尾部注射miR-124-3p agomir或agomir NC后,第4 d摘眼球取血并取出肺组织,ELISA检测血浆中白细胞介素(IL)-1β、IL-6、肿瘤坏死因子α(TNF-α)水平,HE染色观察肺组织病理变化,Western印迹测定TLR4和核转录因子κB(NF-κB)p65蛋白水平。结果:与正常肺组织比较,病毒性肺炎小鼠肺组织miR-124-3p表达量降低(P0.001);miR-124-3p agomir注射组小鼠血浆中IL-1β、IL-6、TNF-α明显低于注射agomir NC组和模型组(P0.001),而高于正常组;HE染色结果表明miR-124-3p agomir注射组小鼠的肺组织炎细胞渗出和浸润较agomir NC组和模型组减轻;与agomir NC组比较,miR-124-3p agomir注射组的TLR4、NF-κB p65表达减少(P0.01)。结论:miR-124-3p抑制TLR4/NF-κB信号通路减轻流感病毒性肺炎小鼠的炎症反应。     

槐果碱抑制糖尿病大鼠肾损伤、NLRP3炎性小体和NF-κB通路活化

目的 观察槐果碱（sophocarpine, SC）对糖尿病大鼠肾损伤的影响,并探讨其相关机制。方法 选用SD大鼠,以高脂饮食12周和链脲佐菌素处理制作糖尿病模型,灌胃给予槐果碱治疗12周。PAS染色以及纤连蛋白（fibronectin, FN）和Cleaved Caspase-3免疫组织化学染色评估肾组织损伤,ELISA检测肾组织中IL-1β及IL-6水平,Western blot检测肾组织中NLRP3、凋亡相关斑点样蛋白（apoptosis-associated speck-like protein containing CARD, ASC）、Cleaved Caspase-1和NF-κB p65蛋白表达水平。结果 糖尿病大鼠肾重指数、尿蛋白排泄水平、血清尿酸水平、肾小球系膜基质扩张系数均较对照大鼠明显升高,肾组织中FN、Cleaved Caspase-3、IL-1β、IL-6、NLRP3、ASC、Cleaved Caspase-1和NF-κB p65蛋白水平均较对照大鼠明显上调,槐果碱干预能明显抑制糖尿病大鼠上述指标变化。结论 槐果碱可能通过抑制NLRP3炎性小体和NF-κB通路...     

乙型肝炎病毒表面抗原抑制TLR2和TLR4的激活

目的　研究乙型肝炎病毒表面抗原(HBsAg) 在乙型肝炎病毒逃逸机体天然免疫中的作用。方法　 PMA诱导THP-1分化成巨噬样细胞,并与乙肝表面抗原（HBsAg）共培养作比较,在LPS （TLR4配体）和pam3csk4（TLR1,2配体）的刺激下,检测细胞上清液中细胞因子IL-10,IL-12的表达及胞内IL-10,IL-12 mRNA 的含量,并利用免疫荧光观察NF-κB p65入核和Western blotting检测IκB-α蛋白降解与ERK蛋白磷酸化水平来判定TLR信号通路活化程度。结果　HBsAg的胞外处理能以剂量依赖的方式干扰pam3csk4和LPS诱导的IL-10和IL-12的产生,同时HBsAg的存在明显干扰pam3csk4和LPS诱导的NF-κB p65入核和IκB-α降解及ERK蛋白磷酸化水平。结论　HBsAg抑制TLR2和TLR4的激活。     

CREB和NF-κB在p38MAPK所致脊髓星形胶质细胞活化中的作用（英文）

目的：探讨CREB和NF-κB在p38MAPK所致脊髓星形胶质细胞活化中的作用,明确脊髓星形胶质细胞活化中p38MAPK细胞信号转导途径的作用。方法：分离培养SPF大鼠脊髓星形胶质细胞,设正常组、SP刺激组（SP组,10-7mol/L）、SP刺激＋SB203580（10μmol/L）阻断p38MAPK组（SP＋SB组）、SP刺激＋PD98059（10μmol/L）阻断CREB组（SP＋PD组）、SP刺激＋SN50（10μmol/L）阻断NF-κB（SP＋SN组）。WB法、免疫荧光法、ELISA法检测12 h和24 h时p-p38、p-CREB、NF-κBp65水平及GFAP、TNF-、IL-1β水平变化。结果：SP组脊髓星形胶质细胞p-p38、p-CREB、NF-κBp65显著升高,GFAP水平显著增高,同时TNF-和IL-1β水平显著增高。与SP组比较,用SB203580阻断p38MAPK通路后,SP＋SB组p-p38、p-CREB、NF-κBp65显著降低,GFAP、TNF-和IL-1β水平显著降低。用PD98059阻断CREB通路后,SP＋PD组p-p38、NF-κBp65无显著变化,p-CREB显著降低,GFAP水平降低,同时TNF-和IL-1β水平降低。用SN50阻断NF-κB通路后,SP＋SN组p-p38、p-CREB无显著变化,NF-κBp65显著降低,GFAP水平降低,同时TNF-和IL-1β水平降低。结论：体外培养中,SP刺激后脊髓星形胶质细胞显著活化,p38MAPK活化后通过CREB及NF-κB信号途径导致胶质细胞炎性因子水平显著升高。     

Interleukin-32 plays an essential role in human calcified aortic valve cells

Interleukin-32 (IL-32) is an inflammatory cytokine produced mainly by T, natural killer, and epithelial cells. Previous studies on IL-32 have primarily investigated its proinflammatory properties. The IL-32 also has been described as an activator of the p38 mitogen-activated protein kinase (MAPK) and NF-κB, and induces several cytokines. In this study, we hypothesized that the inflammatory regulators NF-κB, MAP kinase, STAT1, and STAT3 are associated with the expression of the IL-32 protein in human calcified aortic valve cells. This study comprised aortic valve sclerotic patients and control group patients without calcified aortic valve. Increased IL-32 expression in calcified aortic valvular tissue was shown by immunohistochemical staining and western blotting. There was an increase in NF-κB p65 level, p-ERK, p-JNK, and p-p38 MAPK activation underlying IL-32 expression in the study. The level of p-STAT3 but not p-STAT1 was found to be increased in calcified aortic valve tissue. In cultured primary human aortic valve interstitial cells, inhibition of NF-κB or MAPK kinase pathways results in a decrease of IL-32 expression. Treatment of recombinant IL-32 induced the levels of TNF-α, IL-6, IL-1β, and IL-8. Our findings demonstrate that IL-32 may be an important pro-inflammatory molecule involved in calcific aortic valve disease.     

A20 inhibits the release of inflammatory cytokines by suppressing the activation of the nuclear factor-kappa B pathway in osteoarthritic fibroblast-like synoviocytes

A growing number of studies suggest that synovitis plays an important role in the pathogenesis and progression of osteoarthritis (OA). As a negative mediator of the nuclear factor-kappa B (NF-κB) signaling pathway, the zinc finger protein A20 has significant anti-inflammatory properties. In this study, the differential expression of A20 was investigated at the mRNA and protein levels in human normal OA fibroblast-like synoviocytes (FLSs) and normal FLSs pretreated with TNF-α. We then measured the activation of the NF-κB pathway and expression of pro-inflammatory cytokines in the above three groups by western blotting, a human cytokine array and ELISA. We found that TNF-α activated the NF-κB pathway, increased the expression of the pro-inflammatory cytokines IL-6 and IL-8, and A20 expression in human normal FLSs. However, the role of A20 in FLSs was unclear. To clarify this, we investigated the effect of A20 overexpression in human normal FLSs. The results indicate that A20 inhibits the NF-κB signaling pathway activation and OA-associated pro-inflammatory cytokines release. The results of this study indicate that A20 has anti-inflammatory effects in FLSs, which makes it a potential target for OA synovitis treatment.     

Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products

High sensitivity C-reactive protein (hs-CRP) is synthesized mainly by hepatocytes in response to tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6). The interaction of advanced glycation end products (AGEs) with the receptor for advanced glycation end products (RAGE) increases the expression of the cytokines TNF-α, IL-1, and IL-6. Soluble receptor for advanced glycation end products (sRAGE) competes with RAGE for binding with AGEs. Hence, low sRAGE levels may increase interaction of AGEs with RAGE resulting in the increased production of cytokines. It is hypothesized that serum levels of sRAGE modulate serum levels of hs-CRP. The objectives are to determine if (i) serum levels of sRAGE are lower and those of TNF-α and hs-CRP are higher in non-ST-segment elevation myocardial infarction (NSTEMI) patients compared to control subjects; (ii) serum levels of TNF-α and hs-CRP are positively correlated; and (iii) sRAGE is negatively correlated with hs-CRP and TNF-α. The study consisted of 36 patients with NSTEMI and 30 age-matched healthy male subjects. Serum levels of sRAGE and TNF-α were determined by enzyme-linked immunoassay and hs-CRP was measured using near infrared immunoassay. Serum levels of sRAGE were lower, while those of TNF-α and hs-CRP were higher in patients with NSTEMI compared to controls. The levels of sRAGE were negatively correlated with those of TNF-α and hs-CRP, while TNF-α was positively correlated with hs-CRP in both the control subjects and NSTEMI patients. The data suggest that sRAGE modulates the synthesis of hs-CRP through TNF-α.     

Effect of hypoxia/reoxygenation on the biological effect of IGF system and the inflammatory mediators in cultured synoviocytes

Hypoxia/reoxygenation (H/R) plays an important role in the pathogenesis of osteoarthritis. Fibroblast-like synoviocytes (FLS), which are highly sensitive to H/R, are thought to be associated with cartilage degradation during osteoarthritis development. In this study, we investigated the biological effects of insulin-like growth factor (IGF) system and the expression of inflammatory mediators in FLS. We also pretreated FLS with tumor necrosis factor-α (TNF-α) before H/R in order to observe the response of FLS with the background of inflammatory cytokines. H/R increased the levels of TNF-α-induced C-C chemokine ligand 5 (CCL5), interleukin-1β (IL-1β) and interleukin-6 (IL-6) in cell-free culture supernatants; H/R also increased the expression of TNF-α-induced insulin-like growth factor binding protein 3 (IGFBP-3), downregulated the expression of insulin-like growth factor 1 (IGF-1), promoted the loss of mitochondrial membrane potential (MMP), the openness of mitochondrial permeability transition pore (MPTP), the release of intracellular reactive oxygen species (ROS), and mitochondrial matrix swelling, outer membrane rupture and decrease in cristae. Furthermore, H/R induced the expression of catabolic factors and activated the NF-κB signaling pathway in FLS. We therefore concluded that H/R may play a role in inducing inflammation and increase the TNF-α-induced inflammatory effect in FLS, contributing to osteoarthritis pathogenesis.     

Adiponectin protects palmitic acid induced endothelial inflammation and insulin resistance via regulating ROS/IKKβ pathways

Endothelial inflammation and insulin resistance (IR) has been closely associated with endothelial dysfunction. Adiponectin (APN), an adipocyte-secreted hormone from adipose tissues, showed cardioprotective effects. Here, the protective effect of APN on palmitic acid (PA)-induced endothelial inflammation and IR was investigated. Cultured human umbilical vein endothelial cells (HUVECs) were treated with PA without or without APN pretreatment. The expression of inflammatory cytokines TNF-α, IL-6, adhesion molecule ICAM-1 were determined by western blotting, ELISA, and real-time PCR. The protein expression and protein-protein interaction were determined by western blotting and immunoprecipitation. The intracellular reactive oxygen species (ROS) and nitric oxide (NO) production were monitored with fluorescence probes. PA-induced secretion of TNF-α, IL-6, and expression of ICAM-1 at protein and mRNA levels, which was significantly inhibited by APN. PA treatment caused increase of ROS generation, NOX2, p-IKKβ, p-IκBα, p-p65 expression, and p-IκBα-IKKβ interaction, which were all partly reversed by APN. ROS scavenger N-acetylcysteine (NAC) and NF-κB inhibitor PDTC showed similar effect on PA-induced secretion of TNF-α, IL-6, and expression of ICAM-1. Furthermore, APN and NAC pretreatment restored PA-induced increase of p-IRS-1(S307), decrease of p-IRS-1(Tyr). In addition, insulin-triggered expression of p-IRS-1(Tyr), p-PI3K, p-AKT, p-eNOS and NO generation were inhibited by PA, which were also restored by both APN and NAC. These results suggested that APN ameliorated endothelial inflammation and IR through ROS/IKKβ pathway. This study shed new insights into the mechanisms of APN’s cardiovascular protective effect.     

Cucurbitacin B suppresses the transactivation activity of RelA/p65

Cucurbitacin B, a natural triterpenoid is well-known for its strong anticancer activity, and recent studies showed that the compound inhibits JAK/STAT3 pathway. In this study, we demonstrate for the first time that cucurbitacin B is also a potent inhibitor of NF-κB activation. Our results showed that cucurbitacin B inhibited TNF-α-induced expression of NF-κB reporter gene and NF-κB target genes in a dose-dependent manner, however, it did not prevent either stimuli-induced degradation of IκBα or nuclear translocation and DNA-binding activity of NF-κB. On the other hand, cucurbitacin B dose-dependently suppressed not only NF-κB activation induced by overexpression of RelA/p65 but also transactivation activity of RelA/p65 subunit of NF-κB. Consistently, treatment of HeLa cells with the compound significantly suppressed TNF-α-induced activation of Akt and phosphorylation of Ser536 in RelA/p65, which is required for transactivation activity. Consequently, cucurbitacin B inhibited TNF-α-induced expression of NF-κB-dependent anti-apoptotic proteins such as c-IAP1, c-IAP2, XIAP, TRAF1, and TRAF2 and sensitized TNF-α-induced cell death. Taken together, our results demonstrated that cucurbitacin B could be served as a valuable candidate for the intervention of NF-κB-dependent pathological condition such as cancer.     

5-Hydroxy-4-methoxycanthin-6-one alleviates dextran sodium sulfate-induced colitis in rats via regulation of metabolic profiling and suppression of NF-κB/p65 signaling pathway

Background5-Hydroxy-4-methoxycanthin-6-one (PQ-A) is the main active compound in Ramulus et Folium Picrasmae, a Chinese herbal medicine commonly used in colitis treatment.PurposeTo clarify PQ-A's role and mechanism in colitis treatment based on a non-targeted metabolomics study.MethodsRats with ulcerative colitis (UC) established with 4% dextran sulfate sodium (DSS) were orally treated with PQ-A. Body weight, disease activity index (DAI), colon length, biochemical parameters (MDA and SOD), and histopathological score in colon tissue were measured. A UPLC-Q-TOF-MS/MS approach-based metabolomics analysis was conducted to explore the underlying mechanisms of PQ-A in colitis treatment. Inflammatory cytokines (TNF-α, IL-1β, IL-6, and IL-10) concentrations in serum and their protein levels in the colon were determined. CD3 and NF-κB/p65 immunohistochemistry in the colon was semi-quantified. The related protein or mRNA in IKK-NF-κB/p65 signaling pathway was measured by Western blotting or RT-PCR, respectively. Potential molecular interactions between PQ-A and NF-κB/p65 was predicted using DS 2.5 software.ResultsPQ-A significantly prevented body weight loss and colonic shortening in colitic rats, and reduced the DAI and histopathologic score as well. PQ-A decreased MDA levels in the UC rat serum and increased those of SOD. Metabolomics results revealed forty-nine differential metabolites as biomarkers of DSS-induced colitis, demonstrating that the path-mechanism of colitis involved the perturbation of eight metabolic pathways, including alpha-linolenic acid and linoleic acid metabolism, sphingolipid metabolism, retinol metabolism, bile acid metabolism, et al. Thirty-six biomarkers were especially reversed to normal-like levels by PQ-A via regulation of alpha-linolenic acid and linoleic acid metabolism, sphingolipid metabolism, and retinol metabolism, which effectively hinted the potential pharmacological mechanism of PQ-A related to NF-κB/p65 inflammatory signaling. Molecular docking results predicted high affinity interaction between PQ-A and NF-κB/p65, involving hydrogen-bond interactions at five amino acid residues, suggesting NF-κB/p65 as a target. PQ-A decreased TNF-α, IL-1β, and IL-6 concentrations in serum and their protein levels in colon tissue in colitic rats. CD3, MYD88, p-IκBα, NF-κB/p65, and p-NF-κB/p65 expression levels decreased, whereas those of IKKβ and IκBα increased in colitic tissue following PQ-A treatment. PQ-A strongly inhibited nuclear translocation of NF-κB/p65.ConclusionsWe provide an overview of PQ-A's possible mechanism of action in colitis treatment based on serum non-targeted metabolomics. PQ-A treatment can protect rats against DSS-induced colitis by suppressing the NF-κB/p65 signaling pathway.